BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMB-101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMB-101\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07266324-8910@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:BMB-101: Phase 2 readout est. (NCT07266324)
DESCRIPTION:BMB-101\, phase 2.\nStudy: A 2-Part Study to Assess Efficacy\, 
 Safety and Tolerability of BMB-101 for the Treatment of Patients With Prad
 er-Willi Syndrome.\nEstimated primary completion: November 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bmb-101#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07266324
URL:https://assetmemo.bio/drug/bmb-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
